These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16265725)

  • 1. [International study on testicular cancer: EORTC 30983: randomized phase II/III study of Taxol-BEP versus BEP in patients with Intermediate Prognosis Germ Cell Cancer].
    Rexer FH
    Urologe A; 2005 Sep; 44(9):1064-5. PubMed ID: 16265725
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
    de Wit R; Louwerens M; de Mulder PH; Verweij J; Rodenhuis S; Schornagel J
    Int J Cancer; 1999 Dec; 83(6):831-3. PubMed ID: 10597204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
    Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ;
    Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
    J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours.
    Lawrence NJ; Chan H; Toner G; Stockler MR; Martin A; Yip S; Wong N; Yeung A; Mazhar D; Pashankar F; Frazier L; McDermott R; Walker R; Tan H; Davis ID; Grimison P;
    BMC Cancer; 2018 Aug; 18(1):854. PubMed ID: 30157803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer.
    Kawai K; Akaza H
    Cancer Sci; 2010 Jan; 101(1):22-8. PubMed ID: 19922501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983.
    de Wit R; Skoneczna I; Daugaard G; De Santis M; Garin A; Aass N; Witjes AJ; Albers P; White JD; Germa-Lluch JR; Marreaud S; Collette L
    J Clin Oncol; 2012 Mar; 30(8):792-9. PubMed ID: 22271474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The chemotherapy of disseminated testicular non-seminomatous germ cell tumors and the clinical research of the EORTC Genitourinary Group.
    Stoter G
    Prog Clin Biol Res; 1985; 203():437-47. PubMed ID: 2421335
    [No Abstract]   [Full Text] [Related]  

  • 9. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
    Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC;
    Ann Oncol; 2014 Jan; 25(1):143-8. PubMed ID: 24356625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: Treatment of metastatic germ cell tumor in a newly diagnosed HIV infected man: use of BEP chemotherapy.
    Mtonga P; Mwafulirwa K; Nyirenda R; Masamba L
    Malawi Med J; 2011 Sep; 23(3):91-3. PubMed ID: 23448004
    [No Abstract]   [Full Text] [Related]  

  • 14. Current medical management of patients with poor-risk metastatic germ-cell tumors.
    Albany C
    Curr Opin Urol; 2018 Sep; 28(5):474-478. PubMed ID: 29979236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy and follow-up for recurrences in localized testicular cancer.
    Boulos S; Mazhar D; Warren AY; Wong HH
    Future Oncol; 2017 May; 13(11):947-950. PubMed ID: 28481147
    [No Abstract]   [Full Text] [Related]  

  • 16. Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.
    Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Recková M; Mego M; Hlavatá Z; Brozmanová K; Risnyovzská Z; Svetlovská D; Koza I
    Neoplasma; 2007; 54(3):240-5. PubMed ID: 17447857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
    de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Fosså SD; Cook P; de Prijck L; Stenning S; Collette L
    J Clin Oncol; 2001 Mar; 19(6):1629-40. PubMed ID: 11250991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
    Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
    J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primum non nocere: do we harm stage I testicular cancer patients less by applying adjuvant chemotherapy than by failing to present this option?
    Oldenburg J; Cullen M; Tandstad T
    Ann Oncol; 2015 Feb; 26(2):255-6. PubMed ID: 25395282
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.